株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
企業レポート

PharmaPoint:慢性骨髄性白血病(CML) - 現在および将来の市場参入企業

PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players

発行 GlobalData 商品コード 270707
出版日 ページ情報 英文 44 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
PharmaPoint:慢性骨髄性白血病(CML) - 現在および将来の市場参入企業 PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players
出版日: 2013年05月15日 ページ情報: 英文 44 Pages
概要

当レポートでは、慢性骨髄性白血病(CML)市場で急成長を遂げている企業について調査分析しており、主要企業の現状と発展因子、CML分野における競合情勢、主要企業プロファイルなどの情報を、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場の見通し

  • 世界市場
    • 予測
    • 発展因子・障壁 - 世界的課題

第4章 現在および将来の企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Novartis
    • BMS
    • Ariad
    • Pfizer

第5章 付録

目次
Product Code: GDHC1011FPR

Abstract

Summary

GlobalData has released its pharma report, "PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing CML Market. The report identifies and analyses the key companies shaping and driving the global CML market. The report provides insight into the competitive CML landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for CML
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of the CML sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving the CML Market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global CML market landscape? Identify, understand and capitalize

About GlobalData

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Novartis
    • 4.3.2. BMS
    • 4.3.3. Ariad
    • 4.3.4. Pfizer

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Diagnosed CML patients
    • 5.4.2. Drug-treated Patients on X Line of Therapy
    • 5.4.3. Drugs Included in Each Therapeutic Class
    • 5.4.4. Launch and Patent Expiry Dates
    • 5.4.5. General Pricing Assumptions
    • 5.4.6. Compliance Assumptions for Oral TKIs
    • 5.4.7. Individual Drug Assumptions
    • 5.4.8. Generic Erosion
    • 5.4.9. Pricing of New Market Entrants
  • 5.5. Physicians and Specialists Included in this Study
  • 5.6. Survey of High Prescribing Physicians
  • 5.7. About the Authors
    • 5.7.1. Authors
    • 5.7.2. Epidemiologists
    • 5.7.3. Global Director of Epidemiology and Clinical Trials Analysis
    • 5.7.4. Global Head of Healthcare
  • 5.8. About GlobalData
  • 5.9. Contact Us
  • 5.10. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for CML, 2012-2022
  • Table 2: Chronic Myeloid Leukemia Market - Drivers and Barriers, 2013
  • Table 3: Key Companies in the CML Market, 2013
  • Table 4: Novartis' CML Portfolio Assessment, 2013
  • Table 5: Novartis SWOT Analysis, 2013
  • Table 6: BMS' CML Portfolio Assessment, 2013
  • Table 7: BMS SWOT Analysis, 2013
  • Table 8: Ariad's CML Portfolio Assessment, 2013
  • Table 9: Ariad SWOT Analysis, 2013
  • Table 10: Pfizer's CML Portfolio Assessment, 2013
  • Table 11: Pfizer SWOT Analysis, 2013
  • Table 12: Key Launch Dates
  • Table 13: Key Patent Expiries
  • Table 14: Physicians Surveyed, by Country

List of Figures

  • Figure 1: Global Sales for CML Therapeutics by Region, 2012-2022
  • Figure 2: Company Portfolio Gap Analysis in CML, 2013-2022
Back to Top